{
  "id": 15707556,
  "title": "McKesson EVP, CIO and CTO Francisco Fraga sells $797,128 in stock",
  "url": "https://urgent.news/2026/10/20/mckesson-evp-cio-and-cto-francisco-fraga-sells-797-128-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-20T05:47:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/mckesson-evp-cio-and-cto-francisco-fraga-sells-797128-in-stock-93CH-4958796"
  },
  "original_language": "en",
  "account": "Francisco Fraga, the Executive Vice President, Chief Information Officer, and Chief Technology Officer of McKesson Corp (NYSE:MCK), recently sold 800.491 shares of the company's common stock on October 15, 2026. The sale, which brought in $797,128, took place at a price of $995.80 per share. This transaction occurred as McKesson's stock price was near its 52-week high of $1,015, indicating a solid year of growth with returns of nearly 29% over the past twelve months.\n\nPost-superior, Mr. Fraga now owns 5,423.496 shares of McKesson common stock, encompassing purchases made on June 30, 2026, and September 30, 2026, through the Fidelity Dividend Reinvestment Plan. The stock sale was carried out under a previously established Rule 10b5-1(c) trading plan, adopted on March 10, 2026.\n\nAnalysts at InvestingPro have labeled McKesson as potentially undervalued at the present time, with 18 additional ProTips available to subscribers. In a recent update, McKesson reported first-quarter fiscal 2027 results that exceeded expectations, with adjusted earnings per share of $9.93, surpassing the estimated $9.64. Revenue also surpassed forecasts, reaching $105.38 billion compared to the expected $103.82 billion.\n\nAs a result of these impressive financials, McKesson has raised its full-year earnings outlook. Furthermore, the company announced its definitive agreement to acquire Precision Medicine Group for around $2.25 billion, aiming to bolster its clinical research and biopharma commercialization services. This acquisition will be incorporated into McKesson's Oncology & Multispecialty segment.\n\nWells Fargo has raised its price target for McKesson to $933 from $812, maintaining an Equal Weight rating. The firm anticipates adjusted earnings per share of $44.60, $49.94, and $56.00 for fiscal years 2027, 2028, and 2029, respectively, suggesting significant year-over-year growth. These recent developments underscore McKesson's strategic moves and robust financial performance.",
  "summary": null,
  "key_points": [
    "Francisco Fraga sold 800.491 McKesson shares on October 15, 2026, for $797,128",
    "Stock price near 52-week high of $1,015 at time of sale",
    "McKesson reported Q1 2027 results exceeding expectations with $105.38B revenue"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}